Therapeutic options for Acinetobacter baumannii infections

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 4, 2008, Pages 587-599

  Vila, Jordi ^a,b   Pachón, Jerónimo ^c,d  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Acinetobacter baumannii; Epidemiology; Multiresistance; Treatment

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE DERIVATIVE; AMPICILLIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COLISTIN; DOXYCYCLINE; GENTAMICIN; IMIPENEM; MEROPENEM; MINOCYCLINE; PIPERACILLIN; POLYMYXIN B; QUINOLONE DERIVATIVE; RIFAMPICIN; SPECTINOMYCIN; STREPTOMYCIN; SULBACTAM; SULTAMICILLIN; TETRACYCLINE; TIGECYCLINE; TOBRAMYCIN; ANTIINFECTIVE AGENT; DRUG DERIVATIVE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIAL INFECTION; BACTERIAL MENINGITIS; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; REVIEW; SURGICAL INFECTION; TRACHEOBRONCHITIS; TREATMENT FAILURE; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; CROSS INFECTION; DRUG COMBINATION; DRUG EFFECT; MICROBIOLOGY; MORTALITY; PATHOGENICITY; PATIENT SELECTION; TREATMENT OUTCOME;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; COLISTIN; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; MINOCYCLINE; PATIENT SELECTION; RIFAMPIN; SULBACTAM; TREATMENT OUTCOME;

EID: 40649109539     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.4.587     Document Type: Review

References (118)

1. Bergogne-Berezin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996;9:148-65
2. Noble WC, Pitcher DG. Microbial ecology of the human skin. Adv Clin Microbiol Ecol 1978;2:245-89
3. Villegas MV, Hartstein AI. Acinetobacter outbreaks, 1977 - 2000. Infect Control Hosp Epidemiol 2003;24:284-95
4. Vila J, Marcos F, Marco MA, et al. In vitro antimicrobial production of β-lactamases, aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 1993;37:138-41
5. Seifert H, Baginski R, Schulze A, Pulverer G. Antimicrobial susceptibility of Acinetobacter species. Antimicrob Agents Chemother 1993;37:750-3
6. Shi ZY, Liu PYF, Lau YJ, et al. Antimicrobial susceptibility of clinical isolates of Acinetobacter baumannii. Diag Micorbiol Infect Dis 1996;24:81-5
7. Friedland I, Stinson L, Ikaiddi M, et al. Phenotypic antimicrobial resistance patterns in Pseudomonas aeruginosa and Acinetobacter: results of a multicenter intensive care unit surveillance study, 1995-2000. Diag Microbiol Infect Dis 2003;45:245-50
8. Karlowsky JA, Draghi DC, Jones ME, et al. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother 2003;47:1681-8
9. Fernández-Cuenca F, Pascual A, Ribera A, et al. Diversidad clonal y sensibilidad a los antimicrobianos de Acinetobacter baumannii aislados en hospitales españoles. Estudio multicéntrico nacional: proyecto GEIH-Ab 2000. Enferm Infecc Microbiol Clin 2004;22:267-71
10. Hoban DJ, Bouchillon SK, Dowzick MJ. Antimicrobial susceptibility of extended-spectrum β-lactamase producers and multidrug-resistant Acinetobacter baumannii throughout the United Status and comparative in vitro activity of tigecycline, a new lycylcycline antimicrobial. Diag Micorbiol Infect Dis 2007;57:423-8
11. Falagas ME, Mourtzoukou EG, Polemis M. Trends in antimicrobial resistance of Acinetobacter baumannii clinical isolates from hospitalised patients in Greece and treatment implications. Clin Microbiol Infect 2007;13:816-9
12. Ko KS, Suh JY, Kwon KT, et al. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J Antimicrob Chemother 2007;60:1163-7
13. Li J, Nation RL, Owen RJ, et al. Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains. Clin Infect Dis 2007;45:594-8
14. Hawley JS, Murray CK, Jorgensen JH. Colistin heteroresistance in Acinetobacter and its association with previous colistin therapy. Antimicrob Agents Chemother 2008;52:351-2
15. Henwood CJ, Gatward T, Warner M, et al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother 2002;49:479-87
16. Seifert H, Stefanik D, Wisplinghoff H. Comparative in vitro activities of tigecycline and 11 other antimicrobial agents against 215 epidemiologically defined multidrug-resistant Acinetobacter baumannii isolates. J Antimicrob Chemother 2006;58:1099-100
17. Insa R, Cercenado E, Goyanes MJ, et al. In vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii and Stenotrophomonas maltophilia. J Antimicrob Chemother 2007;59:583-5
18. Saugar JM, Alarcon T, López-Hernandez S, et al. Activities of polymyxin B and cecropin A-melittin peptide CA(1-8) M(1-18) against a multiresistant strain of Acinetobacter baumannii. Antimicrob Agents Chemother 2002;46:875-8
19. Saugar JM, Ródriguez-Hernandez MJ, De La Torre BG, et al. Activity of cecropin A-melittin hybrid peptides against colistin-resistant clinical strains of Acinetobacter baumannii: molecular basis for the differential mechanism of action. Antimicrob Agents Chemother 2006;50:1251-6
20. Swenson JM, Killgore GE, Tenover FC. Antimicrobial susceptibility testing of Acinetobacter spp. by NCCLS broth microdilution and disk diffusion methods. J Clin Microbiol 2004;42:5102-8
21. Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 2001;39:183-90
22. Tan TY, Ng LSY. Comparison of three standardized disc susceptibility testing methods for colistin. J Antimicrob Chemother 2006;58:864-7
23. Arroyo LA, Garcia-Curiel A, Pachon-Ibañez ME, et al. Reliability of the E-test method for detection of colistin resistance in clinical isolates of Acinetobacter baumannii. J Clin Micorbiol 2007;43:903-5
24. Getchell-White SI, Donowitz LG, Groschel DH. The inanimate environment of an intensive care unit as a potential source of nosocomial bacteria: evidence for long survival of Acinetobacter calcoaceticus. Infect Control Hosp Epidemiol 1989;10:402-7
25. De Vegas EZ, Nieves B, Araque M, et al. Outbreak of infection with Acinetobacter strain RUH 1139 in an intensive care unit. Infect Control Hosp Epidemiol 2006;27:397-403
26. Musa EK, Desai N, Casewell MW. The survival of Acinetobacter calcoaceticus inoculated on fingertips and on formica. J Hosp Infect 1990;15:219-27
27. Goldstein FW, Labigne-Roussel A, Gerbaud G, et al. Transferable plasmid-mediated antibiotic resistance in Acinetobacter. Plasmid 1983;10:138-47
28. Da Silva GJ, Correia M, Vital C, et al. Molecular characterization of bla(IMP-5), a new integron-borne metallo-beta-lactamase gene from an Acinetobacter baumannii nosocomial isolate in Portugal. FEMS Microbiol Lett 2002;215:33-9
29. Gombac F, Riccio ML, Rossolini GM, et al. Molecular characterization of integrons in epidemiologically unrelated clinical isolates of Acinetobacter baumannii from Italian hospitals reveals a limited diversity of gene cassette arrays. Antimicrob Agents Chemother 2002;46:3665-8
30. Ribera A, Roca I, Ruiz J, et al. Partial characterization of a transposon containing the tet(A) determinant in a clinical isolate of Acinetobacter baumannii. J Antimicrob Chemother 2003;52:477-80
31. Ruiz J, Navia MM, Casals C, et al. Integron-mediated antibiotic multiresistance in Acinetobacter baumannii clinical isolates from Spain. Clin Microbiol Infect 2003;9:907-11
32. Nemec A, Dolzani L, Brisse S, et al. Diversity of aminoglycoside-resistance genes and their association with class 1 integrons among strains of pan-European Acinetobacter baumannii clones. J Med Microbiol 2004;53:1233-40
33. Ribera A, Vila J, Fernández-Cuenca F, et al. Type 1 integrons in epidemiologically unrelated Acinetobacter baumannii isolates collected at Spanish hospitals. Antimicrob Agents Chemother 2004;48:364-5
34. SIM-1, in a class 1 integron from Acinetobacter baumannii clinical isolates from Korea. Antimicrob Agents Chemother 2005; 49:4485-91
35. Turton JF, Kaufmann ME, Glover J, et al. Detection and typing of integrons in epidemic strains of Acinetobacter baumannii found in the United Kingdom. J Clin Microbiol 2005;43:3074-82
36. Fournier PE, Vellenet D, Barbe V, et al. Comparative genomics of multidrug resistance in Acinetobacter baumannii. PLoS Genet 2006;2:62-72
37. Sato K, Nakae T. Outer membrane permeability of Acinetobacter calcoaceticus and its implication in antibiotic resistance. J Antimicrob Chemother 1991;28:35-45
38. Vila J, Marti S, Sanchez-Cespedes J. Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii. J Antimicrob Chemother 2007;59:1210-5
39. Vila J, Navia M, Ruiz J, Casals C. Cloning and nucleotide sequence analysis of a gene encoding a OXA-derived β-lactamase in Acinetobacter baumannii. Antimicrob Agents Chemother 1997;41:2757-9
40. Navia M, Ruiz J, Vila J. Characterization of an integron carrying a new class D β-lactamase (OXA-37) in Acinetobacter baumannii. Microb Drug Resist 2002;8:261-5
41. Poirel L, Karim A, Mercat A, et al. Extended-spectrum β-lactamase-producing strain of Acinetobacter baumannii isolated from a patient in France. J Antimicrob Chemother 1999;43:157-65
42. Poirel L, Menuteau O, Agoli N, et al. Outbreak of extended-spectrum β-lactamase VEB-1-producing isolates of Acinetobacter baumannii in a French hospital. J Clin Microbiol 2003;41:3542-7
43. Nagano N, Nagano Y, Cordevant C, et al. Nosocomial transmission of CTX-M-2 β-lactamase producing Acinetobacter baumannii in a neurosurgery ward. J Clin Microbiol 2004;42:3978-84
44. Ruiz M, Martí S, Fernanez-Cuenca F, et al. Prevalence of ISAba1 in epidemiologically unrelated Acinetobacter baumannii clinical isolates. FEMS Microbiol Lett 2007;274:63-6
45. Perilli M, Felici A, Oratore A, et al. Characterization of the chromosomal cephalosporinases produced by Acinetobacter lwoffii and Acinetobacter baumannii clinical isolates. Antimicrob Agents Chemother 1996;40:715-9
46. Bou G, Martínez-Beltran J. Cloning, nucleotide sequencing and analysis of the gene encoding an AmpC β-lactamase in Acinetobacter baumannii. Antimicrob Agents Chemother 2000;44:428-32
47. Hujer KM, Hamza NS, Hujer AM, et al. Identification of a new allelic variant of the Acinetobacter baumannii cephalosporinase, ADC-7 β-lactamase: defining a unique family of class C enzymes. Antimicrob Agents Chemother 2005;49:2941-8
48. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 2006;12:826-36
49. Ruiz M, Marti S, Fernandez-Cuenca F, et al. High prevalence of carbapenem-hydrolysing oxacillinases in epidemiologically related and unrelated Acinetobacter baumannii clinical isolates in Spain. Clin Microbiol Infect 2007;13:1192-8
50. Gehrlen M, Leving H, Cullman W, et al. Imipenem resistance in Acinetobacter baumannii is due to altered penicillin-binding proteins. Chemotherpay 1991;37:405-12
51. Fernandez-Cuenca F, Martinez-Martinez L, Conejo MC, et al. Relationship between β-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii. J Antimicrob Agents 2003;51:565-74
52. Shaw KJ, Rather PN, Hare RS, Miller GH. Molecular genetics of aminoglycoside resistance genes and familial relationship of the aminoglycoside-modifying enzymes. Microbiol Rev 1993;57:138-63
53. Vila J, Ruiz J, Navia J, et al. Spread of amikacin resistance in Acinetobacter baumannii isolated in Spain is due to an epidemic strain. J Clin Microbiol 1999;37:758-61
54. Magnet S, Courvalin P, Lambert T. Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454. Antimicrob Agents Chemother 2001;45:3375-80
55. Vila J, Ruiz J, Goñi P, et al. Mutation in the gyrA gene of quinolone-resistant clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 1995;39:1201-3
56. Vila J, Goñi P, Jimenez De Anta MT. Quinolone resistant mutations in the topoisomerase IV parC gene of Acinetobacter baumannii. J Antimicrob Chemother 1997;39:757-62
57. Vila J. Fluoroquinolone resistance. In: White DG, Alekshun MN, McDermott PF, editors. Frontiers in Antimicrobial Resistance. A Tribute to Stuart B Levy. Washington, DC: ASM Press; 2005. p. 41-52
58. Ribera A, Ruiz J, Jiménez De Anta MT, Vila J. Effect of an efflux pump inhibitor on the MIC of nalidixic acid for Acinetobacter baumannii and Stenotrophomonas maltophilia. J Antimicrob Chemother 2002;49:697-702
59. Higgins PG, Wisplinghoff H, Stefanik D, Seifert H. Selection of topoisomerase mutations and overexpression of adeB mRNA transcripts during an outbreak of Acinetobacter baumannii. J Antimicrob Chemother 2004;54:821-3
60. +-coupled Acinetobacter baumannii multidrug efflux pump belonging to the MATE family of transporters. Antimicrob Agents Chemother 2005;49:4362-4
61. Obana Y, Nishino T, Tanino T. In vitro and in vivo activities of antimicrobial agents against Acinetobacter calcoaceticus. J Antimicrob Chemother 1985;15:441-8
62. Martí S, Fernández-Cuenca F, Pascua] A, et al. Prevalencia de los genes tetA y tetB como mecanismo de resistencia a tetraciclina y minociclina en aislamientos clínicos de Acinetobacter baumannii. Enferm Infecc Microbiol Clin 2006;24:77-80
63. Ribera A, Ruiz J, Vila J. Presence of the TetM determinant in a clinicl isolate of Acinetobacter baumannii. Antimicrob Agents Chemother 2003;47:2310-2
64. Ruzin A, Keeney D, Bradfort PA. AdeABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in Acinetobacter calcoaceticus-Acinetobacter baumannii complex. J Antimicrob Chemother 2007;59:1001-4
65. Peleg AY, Adams J, Paterson DL. Tigecycline efflux as a mechanism for nosusceptibility in Acinetobacter baumannii. 2007;51:2065-9
66. Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006;42:692-9
67. Rodríguez-Baño J, Cisneros JM, Fernandez-Cuenca F, et al; The Spanish Group for Nosocomial Infection (GEIH). Clinical features and epidemiology of Acinetobacter baumannii colonization and infection in Spanish hospitals. Infect Control Hosp Epidemiol 2004;25:819-24
68. Fagon JY, Chastre J, Domart Y, et al. Mortality due to ventilator-associated pneumonia or colonization with Pseudomonas or Acinetobacter species: assessment by quantitative culture of samples obtained by a protected specimen brush. Clin Infect Dis 1996;23:538-42
69. Garnacho J, Sole-Violan J, Sa-Borges M, et al. Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: a matched cohort study. Crit Care Med 2003;31:2478-82
70. Jiménez-Mejías ME, Pachón J, Becerril B, et al. Treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin/ sulbactam. Clin Infect Dis 1997;24:932-5
71. Chen SF, Chang WN, Lu CH, et al. Adult Acinetobacter meningitis and its comparison with non-Acinetobacter Gram-negative bacterial meningitis. Acta Neurol Taiwan 2005;14:131-7
72. Cisneros JM, Reyes MJ, Pachon J, et al. Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin Infect Dis 1996;22:1026-32
73. Kuo LC, Lai CC, Liao CH, et al. Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and prognosis. Clin Microbiol Infect 2007;13:196-8
74. Garnacho-Montero J, Ortiz-Leyba C, Fernández-Hinojosa E, et al. Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Int Care Med 2005;31:649-55
75. Fagon JY, Chastre J, Hance AJ, et al. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 1993;94:281-8
76. Blot S, Vandewoude K, Colardyn F. Nosocomial bacteremia involving Acinetobacter baumannii in critically ill patients: a matched cohort study. Int Care Med 2003;29:471-5
77. Grupper M, Sprecher H, Mashiach T, Finkelstein R. Attributable mortality of nosocomial Acinetobacter bacteremia. Infect Control Hosp Epidemiol 2007;28:293-8
78. Falagas ME, Kopterides P, Siempos II. Attributable mortality of Acinetobacter baumannii infection among critically ill patients. Clin Infect Dis 2006;43:389
79. Gkrania-Klotsas E, Hershow RC. Colonization or infection with multidrug resistant Acinetobacter baumannii may be an independent risk factor for increased mortality. Clin Infect Dis 2006;43:1224-5
80. Garnacho-Montero J, Ortiz-Leyva C, Jiménez-Jiménez FJ, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003;36:1111-8
81. Kwon KT, Oh WS, Song JH, et al. Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. J Antimicrob Chemother 2007;59:525-30
82. Sunenshine HR, Wright MO, Maragakis LL, et al. Multidrug resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 2007;13:97-103
83. Rahal JJ. Novel antibiotics combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006;43:S95-9
84. Corbella X, Ariza J, Ardanuy C, et al. Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii. J Antimicrob Chemother 1998;42:793-802
85. Wood GC, Hanes SD, Croce MA, et al. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter baumannii ventilator-associated pneumonia. Clin Infect Dis 2002;34:1425-30
86. Levin AS, Levy CE, Manrique AE, et al. Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/ sulbactam. Int J Antimicrob Agents 2003;21:58-62
87. Betrosian AP, Frantzeskaki F, Xanthaki A, Georgiadis G. High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii. Scand J Infect Dis 2007;39:38-43
88. Rodríguez-Hernández MJ, Cuberos L, Pichardo C, et al. Sulbactam efficay in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains. J Antimicrob Chemother 2001;47:479-82
89. Plachouras D, Giamarellos-Bourboulis EJ, Kentepozidis N, et al. In vitro postantibiotic effect of colistin on multidrug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 2007;57:419-22
90. Owen RJ, Li J, Nation RL, Spelman D. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2007;59:473-7
91. Kallel H, Hergafi L, Bahloul M, et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Int Care Med 2007;33:1162-7
92. Jiménez-Mejías ME, Pichardo-Guerrero C, Márquez-Rivas FJ, et al. Cerebrospina] fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis. Eur J Clin Microbiol Infect Dis 2002;21:212-4
93. Ng J, Gosbell IB, Kelly JA, et al. Cure of multiresistant Acinetobacter baumannii central nervous infections with intraventricular or intrathecal colistin: case series and literature review. J Antimicrob Chemother 2006;58:1078-81
94. Rodríguez-Hernández MJ, Jiménez-Mejias ME, Pichardo C, et al. Colistin efficacy in an experimental endocarditis model caused by Acinetobacter baumannii. Clin Microbiol Infect 2004;10:581-4
95. Montero A, Ariza J, Corbella X, et al. Efficacy of colistin versus β-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother 2002;46:1946-52
96. Pantopoulou A, Giamarellos-Bourboulis EJ, Raftogannis M, et al. Colistin offers prolonged survival in experimental infection by multiresistant Acinetobacter baumannii: the significance of co-administration of rifampicin. Int J Antimicrob Agents 2007;29:51-5
97. Linden PK, Paterson DL. Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia. Clin Infect Dis 2006;43:S89-94
98. Wolff M, Joly-Guillou ML, Farinotti R, Carbon C. In vivo efficacies of combinations of β-lactams, β-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model. Antimicrob Agents Chemother 1999;43:1406-11
99. Montero A, Ariza J, Corbella X, et al. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother 2004;54:1085-91
100. Pachón-Ibañez ME, Docobo-Pérez F, Jiménez-Mejías ME, et al. Efficacy of rifampin, imipenem, and sulbactam in monotherapy and combination, in the experimental pneumonia caused by panresistant Acinetobacter baumannii. Clin Microbiol Infect 2005;11 Suppl 2:577
101. Pachón-Ibáñez ME, Jiménez-Mejías ME, Pichardo C, et al. Antimicrobial activity of tigecycline (GAR-936) again multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother 2004; 48:4479-81
102. Halstead DC, Abid J, Dowzicky MJ. Antimicrobial susceptibility among Acinetobacter calcoaceticus-baumannii complex and Enterobacteriaceae collected as part of the Tigecycline Evaluation and Surveillance Trial. J Infect 2007;55:49-57
103. Betriu C, Rodriguez-Avial I, Gómez M, et al; The Spanish Tigecycline Group. Antimicrobial activity of tigecycline against clinical isolates of Spanish medical centers. Second multicenter study. Diagn Microbiol Infect Dis 2006;56:437-44
104. Peleg AY, Potoski BA, Rea R, et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 2007;59:128-31
105. Reid GE, Grim SA, Aldeza CA, et al. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 2007;27:1198-201
106. Schafer JJ, Goff DA, Stevenson KB, Mangino JE. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy 2007;27:980-7
107. Thamlikitkul V, Tiengrim S, Tribuddharat C. Comment on: high tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 2007;60:177-8
108. Rodríguez-Hernández MJ, Pachón J, Pichardo C, et al. Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia. J Antimicrob Chemother 2000;45:493-501
109. Bernabeu-Wittel M, Pichardo C, García-Curiel A, et al. Pharmacokinetc/ Pharmacodynamic assessment of the in vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia. Clin Microbiol Infect 2005;11:319-25
110. Pachón-Ibáñez ME, Fernández-Cuenca F, Docobo-Pérez F, et al. Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia model, using rifampicin associated with imipenem or sulbactam. J Antimicrob Chemother 2006;58:689-92
111. Saballs M, Pujol M, Tubau F, et al. Rifampicin/Imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 2006;58:697-700
112. Gleeson T, Petersen K, Mascola J. Successful treatment of Acinetobacter meningitis with meropenem and rifampicin. J Antimicrob Chemother 2005;56:602-3
113. Motaouakkil S, Charra B, Hachimi A, et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Infect 2006;53:274-8
114. Li J, Nation RL, Owen RJ, et al. Antibiograms of multi-drug clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains. Clin Infect Dis 2007;45:594-8
115. Petrosillo N, Chinello P, Proietti MF, et al. Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events. Clin Microbiol Infect 2005;11:682-3
116. Rodríguez-Hernández MJ, Saugar J, Docobo-Perez F, et al. Studies on the antimicrobial activity of cecropin A-melittin hybrid peptides in colistin-resistant clinical isolates of Acinetobacter baumannii. J Antimicrob Chemother 2006;58:95-100
117. Braunstein A, Papo N, Shai Y. In vitro activity and potency of an intravenously injected antimicrobial peptide and its DL amino acid analog in mice infected with bacteria. Antimicrob Agents Chemother 2004;48:3127-9
118. López-Rojas R, Docobo-Pérez F, Pachón-Ibáñez ME, et al. In vivo activity of cecropin A-melittin hybrid peptides (CAMs) against panresistant Acinetobacter baumannii. Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago; 2007